Lab Seeks License to Brew LSD and Magic Mushrooms Legally
Published Date: 9/28/2026
Notice
Summary
Irvine Labs, Inc. wants to become a big-time maker of some powerful controlled substances like LSD and psilocybin for research. People and companies affected can share their thoughts or ask for a hearing by November 27, 2026. This move could boost scientific studies but won’t impact prices or public use right now.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Irvine Labs applied to bulk-manufacture Schedule I drugs
On August 13, 2026, Irvine Labs, Inc. applied to be registered as a bulk manufacturer for several Schedule I controlled substances: ibogaine; lysergic acid diethylamide (LSD); mescaline; peyote; diethyltryptamine (DET); dimethyltryptamine (DMT); psilocybin; and psilocyn. The company says it plans to bulk manufacture these substances for research and development internally and to distribute them to its research customers, and that no other activities for those drug codes would be authorized under the registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19792, Importer of Controlled Substances Application: Benuvia Operations, LLC
Benuvia Operations, LLC wants to import a special drug called Ibogaine for research and future medicine testing. People who make or use this drug can share their thoughts or ask for a hearing by October 28, 2026. This move helps Benuvia develop new treatments but doesn’t allow selling finished medicines yet.
2026-19538, Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to make a lot of a special drug called Tetrahydrocannabinols for testing purposes. People who already make or use this drug can share their thoughts by December 23, 2026, and ask for a hearing by November 23, 2026. This move could help scientists get better testing materials without changing how the drug is used.
2026-19540, Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I)
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
Previous / Next Documents
Previous: 2026-19802, Information on SBA Secondary Market Program
Starting October 1, 2026, the SBA is keeping the minimum maturity ratio for 7(a) loan pools at 89%. This rule helps make sure investors get paid on time by supporting SBA’s payment guarantee. If you deal with SBA loan pools, this update keeps things steady and reliable for your investments.
Next: 2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!